Quick takes on the Social Signals from #ASCO26. 🧬 RASolute-302: @marklewismd 's tweet regarding the standing ovation for RASolute-302 really made that trial stand out. The momentum here was massive, fueled by high expectations from the @RevMedicines PR, #AACR26 presentations,and the high-profile Ben Sasse interviews. ⚔️ PROTEUS: One of the more interesting trials from a social media perspective, as the radiation oncology community on X was highly critical of the trial's surgical paradigm. 🔄 CROWN: Felt a bit like an incredible replay of the Plenary from years ago—steady, practice-confirming data. 🎬 HARMONi-6: Perhaps the most compelling narrative twist. The discussant, Dr. Julie Brahmer, masterfully set up the Plenary audience using The Devil Wears Prada as a research metaphor. It begs the question: Is VEGF back? 🚀 LIBRETTO-432: A massive surprise for many attendees. Lung cancer specialists were thrilled about @LillyOncMed selpercatinib in the adjuvant setting for RET-positive NSCLC. The core takeaway from @christine_lovly presentation was loud and clear: "This is why we test." 🔬 OPTIMA: Really got the breast cancer community excited about using @Veracyte 's test to safely reduce the chemotherapy burden for many of their patients. 📦 WU-KONG28: Had such an interesting vibe. Great data from @Dizal_Global , but it leaves the KOLs asking the same commercial question: Why isn't this readily available to patients in the US yet? Follow the #ASCO26 Pre and Post highlights here: kolpulse.com/kol-pulse-asco2…

Does BsAb chemo/ADC beat monotherapy in R/R LBCL? Real 🌍 data (n=352, CUBIC): Combos trended higher: ORR 64% vs 54%, mOS 16 vs 9 m. Only BsAb-ADC independently predicted CR (OR 3.21). Same toxicity. Catch: combo pts younger & more often 2L. Signal is there 💪🏻 #EHA2026

#EHA2026 PS2078 Nutrition matters in elderly #DLBCL patients #lymsm

Very promising. But see this from 15 years ago. Thal versus bortezomib maintenance. History! We thought we had solved high risk then.

Congrats @RahulBanerjeeMD - great to see these outcomes for functional high risk disease, who have such dismal outcomes with previous standard of care #EHA2026 - looking forward to more treatment domains in @MyelomaAmarc 🇦🇺 ZePFHR platform study for FHR disease

CONGRESS | #EHA2026 | POSTER Wanyan Ouyang, Ruijin Hospital-Shanghai Jiao Tong University School of Medicine, shares a multicenter experience of real-world outcomes with zevorcabtagene autoleucel in patients with MM (N = 136). The ORR was 90.8%, with a CR or better in 68.3% of patients. Among patients with prior BCMA-targeted therapy and GPRC5D CAR T-cell therapy exposure (n = 9), the ORR was 77.8%. The ORRs in patients with and without high-risk cytogenetics were 87.8% and 94.0%, respectively. The most common TRAE was cytopenia. Any grade CRS and ICANS occurred in 73.3% and 5.8% of patients, respectively. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @sjtu1896

CONGRESS | #EHA2026 | PRESENTATION Niels van de Donk presents updated safety run-in results from the MajesTEC-4 study evaluating teclistamab ± lenalidomide versus lenalidomide alone as post-transplant maintenance for NDMM. Teclistamab-based maintenance was associated with grade 1/2 CRS events only and no cases of ICANS. During maintenance, ≥CR rates were 96.7–100% across cohorts, with MRD-negative CR rates at 12 months of 90–100% among evaluable patients. Median PFS was not reached in any cohort, with estimated 24-month PFS rates of 94–96.6%. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @amsterdamumc

𝐄𝐇𝐀 𝟐𝟎𝟐𝟔: After presenting early in vivo CAR-T data showing promising results in 6 patients at #EHA2026, @LegendBiotech CEO Ying Huang discusses the future of these types of treatments. $LEGN Watch the full interview: biotechtv.com/post/legend-bi…

In #CLL improving outcomes means more than controlling disease progression.⁴ Keep the #EHA2026 momentum going and explore this nuanced topic with leading #Hematology expert Prof. Wendtner.

A packed hall before our presentations in #EHA2026 on novel #AMLsm therapies where I am opening the session with our #KOMET007 study combination of #Ziftomenib with 7 3 & later my @YaleCancer colleague Nikolai Podoltsev will present Ph1 of Tuspetinib with aza-ven @YaleHematology

Outstanding presentation by @SusanBal9 from @ONealCancerUAB @uabmedicine during #EHA2026 on arlo-cel for R/R myeloma also with participation of @End_myeloma. @ASH_hematology @BloodPortfolio @icmlf

▶️Primary results of BRUIN #CLL322 expertly presented by @DrMDavids as LBA PVR vs VR in RR CLL 2Y PFS 86.9% vs 71.8% Esp. prominent benefit in - cBTKi resistance - TP53 mutation - 1L cBTKi subgroups Practice changing RCT In press @TheLancet #EHA2026 #Pirtobrutinib #PVR

CONGRESS | #EHA2026 | PRESENTATION Binod Dhakal presents long-term follow-up results from the phase I CaMMouflage trial evaluating CB-011, an allogeneic anti-BCMA CAR T-cell therapy with immune cloaking, for the treatment of RRMM (N = 48). Among BCMA-naïve patients treated at the recommended expansion dose (450M CAR-T cells; n = 12), CB-011 demonstrated an ORR of 92% and a ≥CR rate of 83%. MRD negativity (10^-5) was observed in 91% of evaluable patients (n = 11). Grade ≥3 infections and CRS occurred in 25% and 8%, respectively. There were no instances of GvHD, IEC-EC, parkinsonism, or cranial nerve palsies. Enrolment in the dose-expansion portion is ongoing in both BCMA-naïve and BCMA-exposed patients. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @bhemato

Original Article: Talquetamab–Daratumumab in Relapsed or Refractory Myeloma (phase 3 MonumenTAL-3 trial) nej.md/4ojBcCL #EHA2026 | @EHA_Hematology

CONGRESS | #EHA2026 | PRESENTATION Amer Zeidan, Yale School of Medicine, presents long-term results from the KOMET-007 trial of ziftomenib intensive induction (7 3) in patients with ND NPM1-mutated (n = 49) or KMT2A-rearranged (n = 50) AML. The safety profile of ziftomenib 7 3 was consisted with that of 7 3 alone, with TRAEs of any grade reported in 86% of patients and Grade ≥3 TRAEs reported in 53% of patients. The most common Grade ≥3 TEAEs in patients with NPM1-mutated disease were thrombocytopenia (63%), febrile neutropenia (59%), anemia (41%), and neutropenia (33%). The most common Grade ≥3 TEAEs in patients with KMT2A-rearranged disease were febrile neutropenia (66%), thrombocytopenia (56%), anemia (34%), leukopenia (32%), and neutropenia (30%). The ORRs in patients with NPM1-mutated and KMT2A-rearranged disease were 98% and 92%, respectively, with CRs in 94% and 82%. CRc MRD-negativity was achieved in 85% and 82% of patients, respectively. The median DoCR was NR in the NPM1-mutated group and was 12.0 months in the KMT2A-rearranged group. Median OS was NR in either group. Follow our live feed for more updates: loom.ly/XyM7Jss Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #AMLsm #MedicalCongress #MedEd #MedNews @Dr_AmerZeidan @YaleMed

SUCCESSOR-2 #EHA2026 MeziKd vs Kd in anti-CD38 LEN-exposed RRMM: 📊 PFS 18.0 vs 8.3 months (HR 0.48 | p<0.0001) ✅ ORR 80% | ≥CR 27% | VGPR doubled, CR tripled Not competing with bispecifics or CAR-T. Complementing them :earlier, broader, more scalable #mmsm

CONGRESS | #EHA2026 | PRESENTATION Enrique Ocio presents final results from the phase I DREAMM-9 study evaluating the optimal dose and schedule of belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone (BVRd) for the treatment of transplant-ineligible NDMM (N = 118). The highest response rates were observed with Q6/8W dosing (ORR, 96%; ≥CR, 88%; MRD negativity, 54%). Within the Q6/8W cohorts, induction with belantamab mafodotin 1.9 mg/kg resulted in deeper responses than the 1.4 mg/kg dose (≥CR, 92% vs 83%). Extended dosing intervals were associated with fewer Grade ≥3 ocular AEs; 86% of first events resolved with Q6/8W dosing, and 100% resolved with Q9/12W and Q12W dosing. These data support the use of belantamab mafodotin 1.9 mg/kg Q8W for 24 weeks, followed by Q12W dosing, in the DREAMM-10 and PrE1005 studies. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd

MajesTEC-3 vs MonumenTAL-3

Excellent #EHA2026 🧵- Something we continue to learn about as we use GPRC5D more in myeloma. We’ll overestimate incidence at first (e.g., dizziness from orthostatic hypotension from wt loss, 1st noted by @AjaiChari ) … but more research & unified AE term will go a long way!

Great talk of @Dr_AmerZeidan : ZIFTOMENIB COMBINED WITH INTENSIVE INDUCTION (7 3) FOR NEWLY DIAGNOSED NPM1‑M OR KMT2A-R ACUTE MYELOID LEUKEMIA (AML): LONG-TERM RESULTS FROM THE KOMET-007 TRIAL #EHA26 #EHA2026 #AML #leusm

📢 Late-Breaking Abstract #EHA2026 The phase 3 BRUIN CLL-322 trial demonstrated superior IRC-assessed PFS with fixed-duration pirtobrutinib venetoclax rituximab versus venetoclax rituximab in previously treated CLL/SLL. ▪️ HR 0.547 ▪️ 24-mo PFS: 86.9% vs 71.8% ▪️ Consistent benefit across high-risk subsets, including TP53 mutation/del(17p), unmutated IGHV, and complex karyotype ▪️ uMRD4: 86% vs 61% ▪️ Favorable safety profile These data support PVR as a potential new standard-of-care option in relapsed/refractory CLL. #CLL #Hematology #EHA2026